Document and Entity Information Document - shares	3 Months Ended
Document and Entity Information Document - shares	Mar. 30, 2019	Jun. 07, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Beyond Meat, Inc.
Entity Central Index Key	0001655210
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	false
Entity Ex Transition Period	false
Document Type	10-Q
Document Period End Date	Mar. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Current Reporting Status	No
Entity Shell Company	false
Amendment Flag	false
Entity Common Stock, Shares Outstanding		60,122,797

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 35,409	$ 54,271
Accounts receivable	16,194	12,626
Inventory	34,281	30,257
Prepaid expenses and other current assets	6,525	5,672
Total current assets	92,409	102,826
Property, plant, and equipment, net	31,861	30,527
Other non-current assets, net	887	396
Total assets	125,157	133,749
Current liabilities:
Accounts payable	11,663	17,247
Wages payable	1,085	1,255
Accrued bonus	3,387	2,312
Accrued expenses and other current liabilities	3,094	2,391
Short-term capital lease liabilities	36	44
Stock warrant liability	2,677	1,918
Total current liabilities	21,942	25,167
Long-term liabilities:
Revolving credit line	6,000	6,000
Long-term portion of bank term loan, net	19,533	19,388
Equipment loan, net	4,914	5,000
Capital lease obligations and other long-term liabilities	406	404
Total long-term liabilities	30,853	30,792
Commitments and Contingencies (Note 9)
Convertible preferred stock:
Convertible preferred stock	199,540	199,540
Stockholders’ deficit:
Common stock, par value $0.0001 per share—60,000,000 shares and 58,669,600 shares authorized at March 30, 2019 and December 31, 2018, respectively; 7,120,933 and 6,951,350 shares issued and outstanding at March 30, 2019 and December 31, 2018, respectively	1	1
Additional paid-in capital	9,142	7,921
Accumulated deficit	(136,321)	(129,672)
Total stockholders’ deficit	(127,178)	(121,750)
Total liabilities, convertible preferred stock and stockholders’ deficit	125,157	133,749
Series A
Convertible preferred stock:
Convertible preferred stock	2,000	2,000
Series B
Convertible preferred stock:
Convertible preferred stock	4,999	4,999
Series C
Convertible preferred stock:
Convertible preferred stock	14,882	14,882
Series D
Convertible preferred stock:
Convertible preferred stock	24,948	24,948
Series E
Convertible preferred stock:
Convertible preferred stock	17,214	17,214
Series F
Convertible preferred stock:
Convertible preferred stock	29,840	29,840
Series G
Convertible preferred stock:
Convertible preferred stock	55,658	55,658
Series H
Convertible preferred stock:
Convertible preferred stock	$ 49,999	$ 49,999

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 30, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	43,882,867	43,882,867
Convertible preferred stock, outstanding (in shares)	41,562,111	41,562,111	39,474,156	39,361,211
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	60,000,000	58,669,600
Common stock, issued (in shares)	7,120,933	6,951,350
Common stock, outstanding (in shares)	7,120,933	6,951,350
Series A
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	3,333,500	3,333,500
Convertible preferred stock, issued (in shares)	3,333,500	3,333,500
Convertible preferred stock, outstanding (in shares)	3,333,500	3,333,500
Series B
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	4,802,260	4,802,260
Convertible preferred stock, issued (in shares)	4,680,565	4,680,565
Convertible preferred stock, outstanding (in shares)	4,680,565	4,680,565
Series C
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	8,076,643	8,076,643
Convertible preferred stock, issued (in shares)	8,076,636	8,076,636
Convertible preferred stock, outstanding (in shares)	8,076,636	8,076,636
Series D
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	8,713,207	8,713,207
Convertible preferred stock, issued (in shares)	8,713,201	8,713,201
Convertible preferred stock, outstanding (in shares)	8,713,201	8,713,201
Series E
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	4,740,531	4,740,531
Convertible preferred stock, issued (in shares)	4,701,449	4,701,449
Convertible preferred stock, outstanding (in shares)	4,701,449	4,701,449
Series F
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	4,866,776	4,866,776
Convertible preferred stock, issued (in shares)	4,866,758	4,866,758
Convertible preferred stock, outstanding (in shares)	4,866,758	4,866,758
Series G
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	5,140,257	5,140,257
Convertible preferred stock, issued (in shares)	5,114,786	5,114,786
Convertible preferred stock, outstanding (in shares)	5,114,786	5,114,786
Series H
Convertible preferred stock, par value (in shares)	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	4,209,693	4,209,693
Convertible preferred stock, issued (in shares)	2,075,216	2,075,216
Convertible preferred stock, outstanding (in shares)	2,075,216	2,075,216

Statements of Operations - USD ($)	3 Months Ended
Statements of Operations - USD ($)	Mar. 30, 2019	Mar. 31, 2018
Income Statement [Abstract]
Net revenues	$ 40,206,000	$ 12,776,000
Cost of goods sold	29,435,000	10,719,000
Gross profit	10,771,000	2,057,000
Research and development expenses	4,498,000	1,605,000
Selling, general and administrative expenses	11,177,000	5,737,000
Restructuring expenses	394,000	294,000
Total operating expenses	16,069,000	7,636,000
Loss from operations	(5,298,000)	(5,579,000)
Other expense, net:
Interest expense	(733,000)	(47,000)
Other, net	(618,000)	(70,000)
Total other expense, net	(1,351,000)	(117,000)
Loss before taxes	(6,649,000)	(5,696,000)
Income tax expense	0	0
Net loss	$ (6,649,000)	$ (5,696,000)
Net loss per common share—basic and diluted (in dollars per share)	$ (0.95)	$ (0.98)
Weighted average common shares outstanding—basic and diluted (in shares)	6,974,301	5,793,801

Statements of Convertible Preferred Stock and Stockholders’ Deficit - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Loans to Related Parties	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2017	39,361,211
Beginning balance at Dec. 31, 2017	$ 148,194
Preferred Stock
Issuance of Series G preferred stock, net of issuance costs of $7 (in shares)	112,945
Issuance of Series G preferred stock, net of issuance costs of $7	$ 1,228
Ending balance (in shares) at Mar. 31, 2018	39,474,156
Ending balance at Mar. 31, 2018	$ 149,422
Beginning balance (in shares) at Dec. 31, 2017		5,724,506
Beginning balance at Dec. 31, 2017	(95,913)	$ 1	$ 4,823	$ (951)	$ (99,786)
Common Stock
Net loss	(5,696)				(5,696)
Exercise of common stock options (in shares)		92,310
Exercise of common stock options	88		88
Share-based compensation	260		260
Ending balance (in shares) at Mar. 31, 2018		5,816,816
Ending balance at Mar. 31, 2018	$ (101,261)	$ 1	5,171	(951)	(105,482)
Beginning balance (in shares) at Dec. 31, 2018	41,562,111
Beginning balance at Dec. 31, 2018	$ 199,540
Ending balance (in shares) at Mar. 30, 2019	41,562,111
Ending balance at Mar. 30, 2019	$ 199,540
Beginning balance (in shares) at Dec. 31, 2018		6,951,350
Beginning balance at Dec. 31, 2018	(121,750)	$ 1	7,921	0	(129,672)
Common Stock
Net loss	$ (6,649)				(6,649)
Exercise of common stock options (in shares)	169,583	169,583
Exercise of common stock options	$ 366		366
Share-based compensation	855		855
Ending balance (in shares) at Mar. 30, 2019		7,120,933
Ending balance at Mar. 30, 2019	$ (127,178)	$ 1	$ 9,142	$ 0	$ (136,321)

Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Mar. 30, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (6,649)	$ (5,696)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,905	733
Share-based compensation expense	855	260
Amortization of debt issuance costs	58	9
Change in preferred and common stock warrant liabilities	759	129
Net change in operating assets and liabilities:
Accounts receivables	(3,568)	(991)
Inventories	(4,025)	(1,144)
Prepaid expenses and other assets	122	60
Accounts payable	(4,349)	1,845
Accrued expenses and other current liabilities	1,608	(133)
Long-term liabilities	4	40
Net cash used in operating activities	(13,280)	(4,888)
Cash flows used in investing activities:
Purchases of property, plant and equipment	(3,795)	(3,719)
Proceeds from sale of fixed assets	132	0
Purchases of property, plant and equipment held for sale	(829)	0
Payment of security deposits	(501)	(13)
Net cash used in investing activities	(4,993)	(3,732)
Cash flows from financing activities:
Proceeds from Series G preferred stock offering, net of offering costs	0	1,229
Repayments on revolving credit line	0	(2,500)
Repayments on term loan	0	(125)
Payments of capital lease obligations	(9)	(59)
Proceeds from exercise of stock options	366	87
Payments of deferred offering costs	(946)	0
Net cash used in financing activities	(589)	(1,368)
Net decrease in cash and cash equivalents	(18,862)	(9,988)
Cash and cash equivalents at the beginning of the period	54,271	39,035
Cash and cash equivalents at the end of the period	35,409	29,047
Cash paid during the period for:
Interest	715	38
Non-cash investing and financing activities:
Non-cash additions to property, plant and equipment	589	1,226
Deferred offering costs, accrued not yet paid	$ 69	$ 0

Introduction	3 Months Ended
Introduction	Mar. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Introduction	Introduction The Company Beyond Meat, Inc., a Delaware corporation (the “Company”), is one of the fastest growing food companies in the United States, offering a portfolio of revolutionary plant-based meats. The Company builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating the Company’s plant-based meat products. The Company’s brand commitment, “Eat What You Love,” represents a strong belief that by eating the Company’s plant-based meats, consumers can enjoy more, not less, of their favorite meals, and by doing so, help address concerns related to human health, climate change, resource conservation and animal welfare. The Company’s primary production facilities are located in Columbia, Missouri, and research and development and administrative offices are located in El Segundo, California. In addition to its own production facilities, the Company uses co-manufacturers in various locations in the United States to manufacture its products. The Company sells to a variety of customers in the retail and foodservice channels throughout the United States and internationally through brokers and distributors. All of the Company’s long-lived assets are located in the United States. Initial Public Offering On May 6, 2019, the Company completed its initial public offering (“IPO”) of common stock, in which it sold 11,068,750 shares, including 1,443,750 shares pursuant to the underwriters’ over-allotment option. The shares began trading on the Nasdaq Global Select Market on May 2, 2019. The shares were sold at an IPO price of $25.00 per share for net proceeds of approximately $252.5 million, after deducting underwriting discounts and commissions of $19.4 million and estimated offering expenses of approximately $4.8 million payable by the Company. Upon the closing of the IPO, all outstanding shares of the Company’s convertible preferred stock automatically converted into 41,562,111 shares of common stock on a one-for-one basis, and warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 160,767 shares of common stock. The accompanying condensed financial statements as of March 30, 2019, including share and per share amounts, do not give effect to the IPO, conversion of the convertible preferred stock, conversion of the convertible preferred stock warrants as of the IPO and such conversions were completed subsequent to March 30, 2019.

Summary of Significant Accounting Policies

3 Months Ended

Mar. 30, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation

The unaudited condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the condensed financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These condensed financial statements should be read in conjunction with the Company's audited financial statements and notes thereto included in the prospectus dated May 1, 2019 (the “Prospectus”) that forms a part of the Company's Registration Statement on Form S-1 (File No. 333-228453), as filed with the SEC pursuant to Rule 424 promulgated under the Securities Act of 1933, as amended, on May 3, 2019. The condensed balance sheet as of December 31, 2018 has been derived from the audited financial statements at that date. There have been no material changes in the Company’s significant accounting policies from those that were disclosed in the Prospectus, except as noted below.

Fiscal Year

The Company operates on a fiscal calendar year, and each interim quarter is comprised of one 5-week period and two 4-week periods, with each week ending on a Saturday. The Company’s fiscal year always begins on January 1 and ends on December 31. As a result, the Company’s first and fourth fiscal quarters may have more or fewer days included than a traditional 91-day fiscal quarter.

Management’s Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates made by the Company include trade promotion accruals; useful lives of property, plant and equipment; valuation of deferred tax assets; valuation of inventory; and the valuation of the fair value of common stock and preferred stock used to determine stock compensation expense and in the re-measurement of warrants and liabilities. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates and such differences may be material to the condensed financial statements.

Reverse Stock Split

On January 2, 2019, the Company effected a 3-to-2 reverse stock split of its outstanding common stock and convertible preferred stock, including outstanding stock options and common and convertible preferred stock warrants. The reverse stock split did not result in an adjustment to par value. All references in the accompanying condensed financial statements and related notes to the number of shares of common stock, convertible preferred stock, warrants and options to purchase common stock and per share data reflect the effect of the reverse stock split.

Cash and Cash Equivalents

The Company maintains cash balances at one financial institution in the United States. The cash balances may, at times, exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation or FDIC up to $250,000. The Company considers all highly liquid investments with original maturity dates of 90 days or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.

Deferred Offering Costs

Offering costs, consisting primarily of legal, accounting, printing and filing services, and other direct fees and costs related to the IPO, are capitalized. As of March 30, 2019 and December 31, 2018, $3.4 million and $3.2 million of offering costs, respectively, have been capitalized and recorded in prepaid expenses and other current assets in the accompanying condensed balance sheets.

Stock Warrant Liability

The Company accounts for freestanding warrants to purchase shares of its convertible preferred stock or common stock as a liability, as the underlying shares of convertible preferred stock and common stock are contingently redeemable and, therefore, may obligate the Company to transfer assets at some point in the future. The warrants were recorded at fair value upon issuance and are subject to re-measurement at each balance sheet date. Any change in fair value is recognized in the condensed statements of operations in other expense.

As of March 30, 2019, the Company had outstanding warrants to purchase an aggregate of 60,002 shares of its common stock at an exercise price of $3.00 per share, 121,694 shares of its Series B convertible preferred stock at an exercise price of $1.07 per share and 39,073 shares of its Series E convertible preferred stock at an exercise price of $3.68 per share. On May 6, 2019, upon the closing of the IPO, the warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 160,767 shares of common stock at the same respective exercise price per share. Subsequent to the closing of the IPO, all outstanding warrants to purchase shares of common stock were exercised.

Fair Value of Financial Instruments

The fair value measurement accounting guidance creates a fair value hierarchy to prioritize the inputs used to measure fair value into three categories. A financial instrument’s level within the fair value hierarchy is based on the lowest level of input significant to the fair value measurement, where Level 1 is the highest and Level 3 is the lowest.

The three levels are defined as follows:


•	Level 1—Unadjusted quoted prices in active markets accessible by the reporting entity for identical assets or liabilities. Active markets are those in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.


•	Level 2—Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active and model-derived valuations in which significant value drivers are observable.


•	Level 3—Valuations derived from valuation techniques in which significant value drivers are unobservable.

The Company’s financial instruments include cash equivalents, accounts receivable, accounts payable, and accrued expenses, for which the carrying amounts approximate fair value due to the short-term maturity of these financial instruments. Based on the borrowing rates currently available to the Company for debt with similar terms, the carrying value of the line of credit, term debt with its bank, and equipment loan approximate fair value as well.

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis based on the fair value hierarchy (in thousands):



	March 30, 2019
	Level 1		Level 2		Level 3		Total
Financial Liabilities:
Preferred stock warrant liability	$	—	$	—	$	1,998	$	1,998
Common stock warrant liability	—		—		679		679
Total	$	—	$	—	$	2,677	$	2,677

	December 31, 2018
	Level 1		Level 2		Level 3		Total
Financial Liabilities:
Preferred stock warrant liability	$	—	$	—	$	1,441	$	1,441
Common stock warrant liability	—		—		477		477
Total	$	—	$	—	$	1,918	$	1,918

There were no transfers of financial assets or liabilities between Level 1, Level 2 or Level 3 in the three months ended March 30, 2019 or March 31, 2018. The key assumptions used in the Black-Scholes option-pricing model for the valuation of the preferred stock warrant liability and common stock warrant liability upon re-measurement were as follows:



	For the Three Months Ended
	March 30, 2019			March 31, 2018
Expected term (in years)	2.0			3.0
Fair value of underlying shares	$	19.49		$	3.00
Volatility	55.0		%	55.0		%
Risk-free interest rate	2.27		%	1.98		%
Dividend yield	—			—

Generally, increases or decreases in the fair value of the underlying convertible preferred stock and common stock would result in a directionally similar impact in the fair value measurement of the associated warrant liability.

The following table sets forth a summary of the changes in the fair value of the preferred and common stock warrant liabilities:



	For the Three Months Ended
(in thousands)	March 30, 2019		March 31, 2018
Beginning balance	$	1,918	$	550
Change in fair value of warrant liability	759		129
Ending balance	$	2,677	$	679

Revenue Recognition

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which, along with subsequent ASUs, amends the existing accounting standards for revenue recognition (“Topic 606”). This guidance is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled to receive when products are transferred to customers. ASU 2014-09 was effective for the Company beginning January 1, 2019. The majority of the Company’s contracts with customers generally consist of a single performance obligation to transfer promised goods. Based on the Company’s evaluation process and review of its contracts with customers, the timing and amount of revenue recognized based on ASU 2014-09 is consistent with the Company’s revenue recognition policy under previous guidance. The Company has therefore concluded that the adoption of ASU 2014-09 did not have a material impact on its financial position, results of operations, or cash flows.

Revenue is recognized at the point in which the performance obligation under the terms of a contract with the customer have been satisfied and control has transferred. The Company’s performance obligation is typically defined as the accepted purchase order, or the contract, with the customer which requires the Company to deliver the requested products at agreed upon prices at the time and location of the customer’s choice. The Company does not offer warranties or a right to return on the products it sells except in the instance of a product recall.

Revenue is measured as the amount of consideration the Company expects to receive in exchange for fulfilling the performance obligation. Sales and other taxes the Company collects concurrent with the sale of products are excluded from revenue. The Company's normal payment terms vary by the type and location of its customers and the products offered. The time between invoicing and when payment is due is not significant. None of the Company's contracts as of March 30, 2019 contain a significant financing component.

The Company routinely offers sales discounts and promotions through various programs to its customers and consumers. These programs include rebates, temporary on shelf price reductions, off invoice discounts, retailer advertisements, and other trade activities. Provision for discounts and incentives are recorded in the same period in which the related revenues are recognized. At the end of each accounting period, the Company recognizes a liability for estimated sales discounts that have been incurred but not paid which totaled $0.9 million and $0.8 million as of March 30, 2019 and December 31, 2018, respectively. The offsetting charge is recorded as a reduction of revenues in the same period when the expense is incurred.

The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental cost to obtain contracts was not material.

The Company’s net revenues by platform and channel are included in the tables below:



	For the Three Months Ended
(in thousands)	March 30, 2019			March 31, 2018
Net revenues:
Fresh Platform	$	38,806		$	9,596
Frozen Platform	4,512			4,748
Less: Discounts	(3,112		)	(1,568		)
Net revenues	$	40,206		$	12,776



	For the Three Months Ended
(in thousands)	March 30, 2019		March 31, 2018
Net revenues:
Retail	$	19,579	$	9,288
Restaurant and Foodservice	20,627		3,488
Net revenues	$	40,206	$	12,776

Two distributors each accounted for approximately 21% of the Company’s gross revenues in the three months ended March 30, 2019; and three distributors accounted for approximately 34%, 14% and 11%, respectively, of the Company’s gross revenues in the three months ended March 31, 2018, which were primarily related to sales in the United States and Canada. Approximately 14% of the Company’s net revenues in the three months ended March 30, 2019 was from international sales excluding sales in Canada. International sales in the three months ended March 31, 2018 were immaterial.

Shipping and Handling Costs

Outbound shipping and handling costs included in selling, general and administrative (“SG&A”) expenses in the three months ended March 30, 2019 and March 31, 2018 were $1.3 million and $1.1 million, respectively.

Related-Party Transactions

Seth Goldman

The Company entered into a consulting agreement with Seth Goldman, the Company’s Executive Chair, on March 2, 2016, which was amended and restated on November 15, 2018 and further amended on April 8, 2019. Pursuant to the consulting agreement, the Company will pay Mr. Goldman $20,210.33 per month for services rendered under the consulting agreement and, on the date of each annual meeting of the Company’s stockholders after which Mr. Goldman’s non-employee service on the board of directors will continue, the Company has agreed to grant Mr. Goldman a restricted stock unit award under the 2018 Equity Incentive Plan (the “Plan”), having a grant date fair value of $105,000. Each restricted stock unit grant will vest based on continued service in equal monthly installments over the 12-month period following the grant date, provided it will vest in full immediately prior to, and contingent upon, a change in control of the company.

The consulting agreement may be terminated by either party at any time upon 120 business days’ written notice. In the event of a default in the performance of the consulting agreement or material breach of any obligations under the consulting agreement, the non-breaching party may terminate the consulting agreement immediately if the breaching party fails to cure the breach within 30 business days after having received written notice by the non-breaching party of the default or breach.

Bernhard van Lengerich

The Company first entered into an advisor agreement with Food System Strategies, LLC in October 2015. Bernhard van Lengerich. Ph.D., a member of the Company’s Board of Directors, is the Chief Executive Officer of Food System Strategies, LLC. Pursuant to this advisor agreement, the Company paid Food System Strategies, LLC $4,000 for each day Dr. van Lengerich provided services, provided the Company paid Food System Strategies, LLC for at least two days of services per month. In February 2016, the Company entered into a new advisor agreement with Food System Strategies, LLC, which superseded the original agreement and provided for a $25,000 monthly retainer and a non-qualified stock option covering 798,848 shares, which vested in equal monthly installments over three years in consideration of Dr. van Lengerich providing services as the Company’s interim Chief Technical Officer and head of research and development, and the increased time commitment associated with these roles. In December 2016, the advisor agreement was amended to provide for a $10,000 monthly retainer to reflect the fact that Dr. van Lengerich would only be providing advisory services five to six days a month going forward. The advisor agreement may be terminated at any time upon written notice to the other party.

Donald Thompson

In the three months ended March 31, 2018, the Company incurred consulting costs payable to a company associated with Donald Thompson, a member of the Company’s Board of Directors, in the amount of $47,162. The Company did not incur any such consulting costs in the three months ended March 30, 2019.

Recently Adopted Accounting Pronouncements

In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). Under ASU 2018-07, the measurement of equity-classified nonemployee awards will be fixed at the grant date, and nonpublic entities are allowed to account for nonemployee awards using certain practical expedients that are already available for employee awards. The amendments in ASU 2018-07 are effective for nonpublic business entities for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than the Company’s adoption date of Topic 606. The Company early adopted ASU 2018-07 beginning January 1, 2019 along with its adoption of ASU 2014-09. Pursuant to ASU 2018-07, the measurement of equity classified nonemployee awards will be fixed at the grant date, as compared to the previous requirement to remeasure the awards through the performance completion date.

New Accounting Pronouncements

As an “emerging growth company,” the Jumpstart Our Business Startups Act, or the JOBS Act, allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use the adoption dates applicable to private companies. As a result, the Company’s financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies.

In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”), which makes amendments to the guidance in GAAP on the classification and measurement of financial instruments. ASU 2016-01 significantly revises an entity’s accounting related to (1) the classification and measurement of investments in equity securities and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. It also amends certain disclosure requirements associated with the fair value of financial instruments. For all entities other than public entities, ASU 2016-01 is effective for fiscal years beginning after December 15, 2018, including interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company expects to adopt and implement ASU 2016-01 for the year ending December 31, 2019 and for interim periods beginning January 1, 2020. The Company does not expect that adoption of ASU 2016-01 will have a material impact on the Company’s financial position, results of operations, or cash flows.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires lessees to generally recognize most operating leases on the balance sheets but record expenses on the income statements in a manner similar to current accounting. ASU 2016-02 along with subsequent ASU’s on Topic 842 is effective for nonpublic companies for the annual reporting period beginning after December 15, 2019, and, therefore, effective for the Company beginning January 1, 2020. Early application is permitted. The Company is currently evaluating the impact ASU 2016-02 will have on its financial statements and currently expects that most operating lease commitments will be subject to ASU 2016-02 and will be recognized as operating lease liabilities and right-of-use assets upon adoption. While the Company has not yet quantified the impact, adjustments resulting from the adoption of ASU 2016-02 will materially increase total assets and total liabilities relative to such amounts reported prior to adoption.

Restructuring	3 Months Ended
Restructuring	Mar. 30, 2019
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In May 2017, management approved a plan to terminate the Company’s exclusive supply agreement (the “Agreement”) with one of its co-manufacturers, due to non-performance under the Agreement and on May 23, 2017, the Company notified the co-manufacturer of its decision to terminate the Agreement. In the three months ended March 30, 2019 and March 31, 2018, the Company recorded $0.4 million and $0.3 million, respectively, in restructuring expenses related to this dispute, which consisted primarily of legal and other expenses. See Note 9 for further information. As of March 30, 2019 and December 31, 2018, there were no accrued unpaid liabilities associated with this contract termination.

Property, Plant and Equipment

3 Months Ended

Mar. 30, 2019

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant, and equipment are stated at cost and capital lease assets are included. A summary of property, plant, and equipment as of March 30, 2019 and December 31, 2018, is as follows:



(in thousands)	March 30, 2019		December 31, 2018
Manufacturing equipment	$	28,866	$	25,314
Research and development equipment	7,111		6,088
Leasehold improvements	7,166		7,080
Capital leases	883		882
Software	125		60
Furniture and fixtures	203		195
Vehicles	210		210
Assets not yet placed in service	1,877		3,374
Total property, plant and equipment	$	46,441	$	43,203
Less: accumulated depreciation and amortization	14,580		12,676
Property, plant and equipment, net	$	31,861	$	30,527

Depreciation and amortization expense for the three months ended March 30, 2019 and March 31, 2018, was $1.9 million and $0.7 million, respectively. Of the total depreciation and amortization expense in the three months ended March 30, 2019 and March 31, 2018, $1.4 million and $0.6 million, respectively, were recorded in cost of goods sold and $0.5 million and $0.1 million, respectively, were recorded in research and development expenses in the Company’s condensed statements of operations.

The Company has $1.9 million and $1.0 million in property, plant and equipment concluded to meet the criteria for assets held for sale and are included in prepaid expenses and other current assets on the condensed balance sheets as of March 30, 2019 and December 31, 2018, respectively. The Company expects to sell such assets in 2019 for amounts that approximate book value.

Debt

3 Months Ended

Mar. 30, 2019

Debt Disclosure [Abstract]

Debt

The Company’s debt balances are detailed below:



(in thousands)	March 30, 2019			December 31, 2018
2018 Revolving Credit Facility (defined below)	$	6,000		$	6,000
2018 Term Loan Facility (defined below)	20,000			20,000
Equipment financing loan	5,000			5,000
Debt issuance costs	(553		)	(612		)
Total debt outstanding	$	30,447		$	30,388
Less: current portion of long-term debt	—			—
Long-term debt	$	30,447		$	30,388

The Company records debt issuance costs as a reduction of carrying value of the debt in the accompanying condensed balance sheets. Debt issuance costs, net of amortization, totaled $0.6 million as of March 30, 2019 and December 31, 2018. Debt issuance costs are amortized as interest expense over the term of the loan for which amortization of $58,000 and $9,000 was recorded during the three months ended March 30, 2019 and March 31, 2018, respectively.

Amended and Restated Loan and Security Agreement

In June 2018, the Company refinanced its then existing revolving credit facility and term loan facility under a loan and security agreement with Silicon Valley Bank (“SVB”) (the “Amended LSA”). The Amended LSA includes a $6.0 million revolving credit facility (the “2018 Revolving Credit Facility”) and a term loan facility (the “2018 Term Loan Facility”) comprised of (i) a $10.0 million term loan advance at closing, (ii) a conditional $5.0 million term loan advance, if no event of default has occurred and is continuing through the borrowing date, and (iii) an additional conditional term loan advance of $5.0 million if no event of default has occurred and is continuing based upon a minimum level of gross profit for the trailing 12-month period. The 2018 Term Loan Facility has a floating interest rate that is equal to 4.0% above the prime rate, with interest payable monthly and principal amortizing commencing on January 1, 2020, and will mature in June 2022. Borrowings under the 2018 Revolving Credit Facility carry a variable annual interest rate of prime rate plus 0.75% to 1.25% with an additional 5% on the outstanding balances in the event of a default. The 2018 Revolving Credit Facility matures in June 2020.

The 2018 Term Loan Facility and the 2018 Revolving Credit Facility (the “SVB Credit Facilities,”) contain customary negative covenants that limit the Company’s ability to, among other things, incur additional indebtedness, grant liens, make investments, repurchase stock, pay dividends, transfer assets and merge or consolidate. The SVB Credit Facilities are secured by a blanket lien on all of the Company’s personal property assets. The SVB Credit Facilities also contain customary affirmative covenants, including delivery of audited financial statements. The Company was in compliance with the covenants in the SVB Credit Facilities as of March 30, 2019.

As of March 30, 2019 and December 31, 2018, the Company had $6.0 million and $20.0 million in borrowings on the 2018 Revolving Credit Facility and 2018 Term Loan Facility, respectively, and had no availability to borrow under either of these loan facilities. In the three months ended March 30, 2019 and March 30, 2018, the Company incurred $0.6 million and $18,000 in interest expense related to the SVB credit facilities. The interest rates on the 2018 Revolving Credit Facility and the 2018 Term Loan Facility at March 30, 2019 were 6.25% and 9.50%, respectively.

Equipment Loan Facility

The Company had $5.0 million in borrowings outstanding as of March 30, 2019 and December 31, 2018 under the equipment loan facility. The interest rate on the equipment loan facility at March 30, 2019 and December 31, 2018 was 11.75% and 11.5%, respectively. For the three months ended March 30, 2019 and March 31, 2018, the Company recorded $0.1 million and $0, respectively, in interest expense related to the equipment loan facility.

Warrant Liabilities

In connection with its financing arrangements, the Company has issued warrants to purchase shares of its convertible preferred stock. For one of the financing arrangements, the Company issued warrants to purchase 121,694 shares of Series B convertible preferred stock at an exercise price of $1.07 per share. For a separate financing arrangement, the Company issued warrants to purchase 39,073 shares of Series E convertible preferred stock at an exercise price of $3.68 per share. In connection with the Company’s refinancing of its credit facilities with SVB, the Company issued to SVB and its affiliates warrants to purchase an aggregate of 60,002 shares of its common stock at an exercise price of $3.00 per share. The warrants remained outstanding as of March 30, 2019 and December 31, 2018. On May 6, 2019, upon the closing of the IPO, the warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 160,767 shares of common stock at the same respective exercise price per share. Subsequent to the closing of the IPO, all outstanding warrants to purchase shares of common stock were exercised. See Note 2 for further information on the warrant liabilities.

Stockholders’ Deficit and Convertible Preferred Stock	3 Months Ended
Stockholders’ Deficit and Convertible Preferred Stock	Mar. 30, 2019
Equity [Abstract]
Stockholders’ Deficit and Convertible Preferred Stock	Stockholders’ Deficit and Convertible Preferred Stock As of March 30, 2019, the Company’s shares consisted of 60,000,000 authorized shares of common stock, par value $0.0001 per share, of which 7,120,933 shares were issued and outstanding, and 43,882,867 authorized shares of preferred stock, par value $0.0001 per share, of which 3,333,500 shares of Series A Preferred Stock, 4,680,565 shares of Series B Preferred Stock, 8,076,636 shares of Series C Preferred Stock, 8,713,201 shares of Series D Preferred Stock, 4,701,449 shares of Series E Preferred Stock, 4,866,758 shares of Series F Preferred Stock, 5,114,786 shares of Series G Preferred Stock and 2,075,216 shares of Series H Preferred Stock were issued and outstanding. Upon the closing of the IPO, all outstanding shares of the Company’s convertible preferred stock automatically converted into 41,562,111 shares of common stock on a one-for-one basis. On May 6, 2019, the Company filed an Amended and Restated Certificate of Incorporation authorizing the Company to issue 500,000,000 shares of common stock, $0.0001 par value per share, and 500,000 shares of undesignated preferred stock, $0.0001 par value per share with rights and preferences determined by the Company’s Board of Directors at the time of issuance of such shares. As of December 31, 2018, the Company’s shares consisted of 58,669,600 authorized shares of common stock, par value $0.0001 per share, of which 6,951,350 shares were issued and outstanding, and 43,882,867 authorized shares of preferred stock, par value $0.0001 per share, of which 3,333,500 shares of Series A Preferred Stock, 4,680,565 shares of Series B Preferred Stock, 8,076,636 shares of Series C Preferred Stock, 8,713,201 shares of Series D Preferred Stock, 4,701,449 shares of Series E Preferred Stock, 4,866,758 shares of Series F Preferred Stock, 5,114,786 shares of Series G Preferred Stock and 2,075,216 shares of Series H Preferred Stock were issued and outstanding. The Company has not declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock.

Share-Based Compensation

3 Months Ended

Mar. 30, 2019

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

On April 11, 2011, the Company’s stockholders approved the 2011 Equity Incentive Plan (“2011 Plan”), and most recently amended the 2011 Plan on April 10, 2019. The 2011 Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock and restricted stock unit awards to eligible participants. Eligible participants are employees, directors and consultants. As of March 30, 2019, there were 9,462,455 shares of common stock authorized for issuance under the 2011 Plan.

The 2011 Plan was amended, restated and re-named the 2018 Equity Incentive Plan (“2018 Plan”), which became effective as of April 30, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. The 2018 Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, restricted stock units, performance units, and performance shares to the Company’s employees, directors, and consultants. The maximum aggregate number of shares that may be issued under the 2018 Plan is 14,482,356 shares of the Company’s common stock. In addition, the number of shares reserved for issuance under the 2018 Plan will be increased automatically on the first day of each fiscal year beginning with the 2020 fiscal year, by a number equal to the least of: (i) 2,144,521 shares; (ii) 4.0% of the shares of common stock outstanding on the last day of the prior fiscal year; or (iii) such number of shares determined by the Company’s Board of Directors.

The 2018 Plan may be amended, suspended or terminated by the Company’s Board of Directors at any time, provided such action does not impair the existing rights of any participant, subject to stockholder approval of any amendment to the 2018 Plan as required by applicable law or listing requirements. Unless sooner terminated by the Company’s Board of Directors, the 2018 Plan will automatically terminate on November 14, 2028.

As of March 30, 2019 and December 31, 2018, there were 4,900,328 and 5,120,293 shares, respectively, issuable under stock options outstanding, 4,504,914 and 4,335,331 shares, respectively, issued for stock option exercises and restricted stock grants, and 57,213 and 6,859 shares, respectively, available for grant under the 2011 Plan.

As of March 30, 2019, there were 4,577,114 shares of common stock reserved for future grant or issuance under the 2018 Plan, from which (i) options to purchase 264,033 shares of common stock were granted on April 3, 2019, having an exercise price of $20.02 per share, (ii) options to purchase (A) 1,000,000 shares of common stock were granted on April 18, 2019, (B) 51,999 shares of common stock were granted on April 29, 2019, and (C) 50,000 shares of common stock were granted on May 1, 2019, in each case to be effective upon and subject to the effectiveness of the registration statement relating to the Company’s IPO and having an exercise price equal to the IPO price of $25.00 per share, and (iii) awards covering 99,433 shares of restricted stock were granted on April 18, 2019 at a purchase price of $0.01 per share and which will be issued upon payment of the purchase price.

Stock Options

No stock option grants were awarded in the three months ended March 30, 2019.

The following table summarizes the Company’s stock option activity during the three months ended March 30, 2019:



	Number of Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value (in thousands)⁽¹⁾
Outstanding at December 31, 2018	5,120,293		$	3.13	7.3	$	81,371
Granted	—		$	—	—	$	—
Exercised	(169,583	)	$	2.16	—	$	2,859
Cancelled/Forfeited	(50,382	)	$	4.34	—	$	—
Outstanding at March 30, 2019	4,900,328		$	3.15	7.0	$	80,076
Vested and exercisable at March 30, 2019	2,981,633		$	1.11	5.9	$	54,793
Vested and expected to vest at March 30, 2019	3,967,483		$	2.16	5.9	$	68,759

__________

(1) Aggregate intrinsic value is calculated as the difference between the value of common stock on the transaction date and the exercise price multiplied by the number of shares issuable under the stock option.

During the three months ended March 30, 2019 and March 31, 2018, the Company recorded in aggregate $0.6 million and $0.2 million, respectively, of share-based compensation expense related to options issued to employees and nonemployees. The share-based compensation is included in cost of goods sold and SG&A expenses in the Company’s condensed statements of operations.

As of March 30, 2019 and December 31, 2018, there was $2.3 million and $2.4 million in unrecognized compensation expense related to nonvested stock option awards which is expected to be recognized over 2.7 years and 2.9 years, respectively.

Restricted Stock to Nonemployees

In October 2018, the Company’s Board of Directors approved the issuance of 135,791 shares of restricted stock with a fair value of $17.03 per share and a purchase price of $0.02 per share to nonemployees serving as the Company’s brand ambassadors. The Company has the right to repurchase the unvested shares upon a voluntary or involuntary termination of a brand ambassador’s service; however, as shares vest monthly over 12 to 24 months, they are being released from the repurchase option (and all such shares will be released from the repurchase option by November 1, 2020).

The following table summarizes the Company’s restricted stock activity during the three months ended March 30, 2019:



	Number of Shares of Restricted Stock		Weighted Average Remaining Contractual Life (Years)	Weighted Average Grant Date Fair Value Per Share
Outstanding at December 31, 2018	100,127		1.6	$	17.03
Granted	—		—	$	—
Vested/Released	(12,946	)	—	$	—
Cancelled/Forfeited	—		—	$	—
Outstanding at March 30, 2019	87,181		1.4	$	17.03

During the three months ended March 30, 2019, the Company recorded in aggregate $0.3 million in share-based compensation expense related to restricted stock issued to nonemployee brand ambassadors, which is included in SG&A expenses in the Company’s condensed statements of operations.

As of March 30, 2019, there was $1.4 million in unrecognized compensation expense related to nonvested restricted stock, which is expected to be recognized over 1.4 years.

In April 2019, the Company’s Board of Directors approved the issuance of 99,433 shares of restricted stock with a fair value of $20.02 per share and a purchase price of $0.02 per share to nonemployees serving as the Company’s brand ambassadors. The Company has the right to repurchase the unvested shares upon a voluntary or involuntary termination of a brand ambassador’s service; however, as shares vest monthly over 24 months, they are being released from the repurchase option (and all such shares will be released from the repurchase option by May 18, 2021).

Employee stock purchase plan

On November 15, 2018, the Company’s Board of Directors adopted its 2018 Employee Stock Purchase Plan (“2018 ESPP”), which was subsequently approved by the Company’s stockholders and became effective on April 30, 2019, the day immediately prior to the effectiveness of the registration statement filed in connection with the IPO. The 2018 ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code (the “Code”) for U.S. employees. In addition, the 2018 ESPP authorizes grants of purchase rights that do not comply with Section 423 of the Code under a separate non-423 component for non-U.S. employees and certain non-U.S. service providers. The Company has reserved 804,195 shares of common stock for issuance under the 2018 ESPP. In addition, the number of shares reserved for issuance under the 2018 ESPP will be increased automatically on the first day of each fiscal year for a period of up to ten years, starting with the 2020 fiscal year, by a number equal to the least of: (i) 536,130 shares; (ii) 1% of the shares of common stock outstanding on the last day of the prior fiscal year; or (iii) such lesser number of shares determined by the Company’s Board of Directors. The 2018 ESPP is expected to be implemented through a series of offerings under which participants are granted purchase rights to purchase shares of the Company’s common stock on specified dates during such offerings. The administrator has not yet approved an offering under the 2018 ESPP.

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases Effective March 1, 2019, the Company entered into a lease for its principal executive offices in El Segundo, California, for an initial term of 5 years. The aggregate lease amount for the five-year term is $2.7 million. The future minimum lease payments required under noncancelable lease obligations related to this lease are $2.6 million due through 2023 (approximately $0.5 million annually) and $0.1 million thereafter. Purchase Commitments As of March 30, 2019, the Company had committed to purchase pea protein inventory totaling $46.1 million. Litigation On May 25, 2017, a former co-manufacturer of the Company filed a complaint against the Company in the Superior Court of the State of California for the County of Los Angeles asserting claims for (1) breach of contract, (2) misappropriation of trade secrets, (3) unfair competition under California Business & Professions Code Section 17200 Et. Seq., (4) money owed and due, (5) declaratory relief, and (6) injunctive relief, each arising out of the Company’s decision to terminate an exclusive agreement dated December 2, 2014 between the Company and the former co-manufacturer, pursuant to its terms (see Note 3). The Company denies these claims, filed counter-claims on July 27, 2017, alleging (1) breach of contract, (2) unfair competition under California Business & Professions Code Section 17200 Et. Seq., and (3) conversion, and is in the process of litigating this matter. In October 2018, the former co-manufacturer filed an amended complaint that added one of the Company’s current contract manufacturers as a defendant, principally for claims arising from the current contract manufacturer’s alleged use of the former co-manufacturer’s alleged trade secrets, and for replacing the former co-manufacturer as one of the Company’s current co-manufacturers. The current co-manufacturer filed an answer denying all of the former co-manufacturer’s claims, and a cross-complaint against Beyond Meat asserting claims of total and partial equitable indemnity, contribution, and repayment. On March 11, 2019, the former co-manufacturer filed a second amended complaint to add claims of fraud and negligent misrepresentation against the Company. On May 30, 2019, the judge denied the Company’s motion to dismiss the fraud and negligent misrepresentation claims, allowing the claims to proceed. A trial date has been set for May 18, 2020. At this time the Company cannot reasonably estimate the potential liability associated with this litigation, but believes the final resolution of this litigation will not have a material adverse effect on its financial position, results of operations, or cash flows. The Company is involved in various legal proceedings, claims, and litigation arising in the ordinary course of business. Based on the facts currently available, the Company does not believe that the disposition of matters that are pending or asserted will have a material effect on its financial statements.

Income Taxes	3 Months Ended
Income Taxes	Mar. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended March 30, 2019 and March 31, 2018 the Company recorded no income tax expense in its condensed statements of operations. The Company has evaluated the available evidence supporting the realization of its deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that its net deferred tax assets will not be realized in the U.S. Due to uncertainties surrounding the realization of the deferred tax assets, the Company maintains a full valuation allowance against substantially all deferred tax assets. When the Company determines that it will be able to realize some portion or all of its deferred tax assets, an adjustment to its valuation allowance on its deferred tax assets would have the effect of increasing net income in the period such determination is made. As of March 30, 2019, the Company does not have any accrued interest or penalties related to uncertain tax positions. The Company’s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. The Company is subject to U.S. federal tax authority and U.S. state tax authority examinations for all years with respect to net operating loss and credit carryforwards.

Net Loss Per Share Attributable to Common Stockholders

3 Months Ended

Mar. 30, 2019

Earnings Per Share [Abstract]

Net Loss Per Share Attributable to Common Stockholders

The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for companies with participating securities. The Company considers all series of convertible preferred stock issued and outstanding prior to the IPO to be participating securities. Under the two-class method, the net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holders of convertible preferred stock issued and outstanding prior to the IPO do not have a contractual obligation to share in losses.

The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, options to purchase common stock, common stock warrants and securities such as convertible preferred stock and convertible preferred stock warrants that were issued and outstanding before the Company’s IPO, are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is antidilutive. Basic and diluted net loss per common share was the same for each period presented, as the inclusion of all potential common shares outstanding would have been antidilutive.



(in thousands, except share and per share amounts)	Three Months Ended
(in thousands, except share and per share amounts)	March 30, 2019			March 31, 2018
Numerator:
Net loss attributable to common stockholders	$	(6,649	)	$	(5,696	)
Denominator:
Weighted average common shares outstanding—basic	6,974,301			5,793,801
Dilutive effect of stock equivalents resulting from stock options, common stock warrants, preferred stock warrants and convertible preferred stock (as converted)	—			—
Weighted average common shares outstanding—diluted	6,974,301			5,793,801
Net loss per common share—basic and diluted	$	(0.95	)	$	(0.98	)

The following weighted-average outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because the impact of including them would have been antidilutive:



	March 30, 2019	March 31, 2018
Convertible preferred stock (as converted)	41,562,111	39,474,156
Preferred stock warrants (as converted to common stock warrants and subsequently exercised)	160,767	160,767
Common stock warrants (as exercised)	60,002	—
Total	41,782,880	39,634,923

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 30, 2019

Accounting Policies [Abstract]

Basis of Presentation

Fiscal Year

Management’s Use of Estimates

Cash and Cash Equivalents

Deferred Offering Costs

Offering costs, consisting primarily of legal, accounting, printing and filing services, and other direct fees and costs related to the IPO, are capitalized.

Stock Warrant Liability

Fair Value of Financial Instruments

The three levels are defined as follows:


•	Level 1—Unadjusted quoted prices in active markets accessible by the reporting entity for identical assets or liabilities. Active markets are those in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.


•	Level 2—Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active and model-derived valuations in which significant value drivers are observable.


•	Level 3—Valuations derived from valuation techniques in which significant value drivers are unobservable.

Revenue Recognition

Recently Adopted and New Accounting Pronouncements

Recently Adopted Accounting Pronouncements

New Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 30, 2019

Accounting Policies [Abstract]

Schedule of financial instruments measured at fair value

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis based on the fair value hierarchy (in thousands):



	March 30, 2019
	Level 1		Level 2		Level 3		Total
Financial Liabilities:
Preferred stock warrant liability	$	—	$	—	$	1,998	$	1,998
Common stock warrant liability	—		—		679		679
Total	$	—	$	—	$	2,677	$	2,677

	December 31, 2018
	Level 1		Level 2		Level 3		Total
Financial Liabilities:
Preferred stock warrant liability	$	—	$	—	$	1,441	$	1,441
Common stock warrant liability	—		—		477		477
Total	$	—	$	—	$	1,918	$	1,918

Schedule of assumptions used for valuation

The key assumptions used in the Black-Scholes option-pricing model for the valuation of the preferred stock warrant liability and common stock warrant liability upon re-measurement were as follows:



	For the Three Months Ended
	March 30, 2019			March 31, 2018
Expected term (in years)	2.0			3.0
Fair value of underlying shares	$	19.49		$	3.00
Volatility	55.0		%	55.0		%
Risk-free interest rate	2.27		%	1.98		%
Dividend yield	—			—

Summary of changes in fair value

The following table sets forth a summary of the changes in the fair value of the preferred and common stock warrant liabilities:



	For the Three Months Ended
(in thousands)	March 30, 2019		March 31, 2018
Beginning balance	$	1,918	$	550
Change in fair value of warrant liability	759		129
Ending balance	$	2,677	$	679

Schedule of net revenues by platform and channel

The Company’s net revenues by platform and channel are included in the tables below:



	For the Three Months Ended
(in thousands)	March 30, 2019			March 31, 2018
Net revenues:
Fresh Platform	$	38,806		$	9,596
Frozen Platform	4,512			4,748
Less: Discounts	(3,112		)	(1,568		)
Net revenues	$	40,206		$	12,776



	For the Three Months Ended
(in thousands)	March 30, 2019		March 31, 2018
Net revenues:
Retail	$	19,579	$	9,288
Restaurant and Foodservice	20,627		3,488
Net revenues	$	40,206	$	12,776

Inventories (Tables)

3 Months Ended

Mar. 30, 2019

Inventory Disclosure [Abstract]

Schedule of major classes of inventory

Major classes of inventory were as follows:



	March 31,		December 31,
(in thousands)	2019		2018
Raw materials and packaging	$	16,385	$	13,756
Work in process	6,198		2,517
Finished goods	11,698		13,984
Total	$	34,281	$	30,257

Property, Plant and Equipment (Tables)

3 Months Ended

Mar. 30, 2019

Property, Plant and Equipment [Abstract]

Summary of property, plant, and equipment

A summary of property, plant, and equipment as of March 30, 2019 and December 31, 2018, is as follows:



(in thousands)	March 30, 2019		December 31, 2018
Manufacturing equipment	$	28,866	$	25,314
Research and development equipment	7,111		6,088
Leasehold improvements	7,166		7,080
Capital leases	883		882
Software	125		60
Furniture and fixtures	203		195
Vehicles	210		210
Assets not yet placed in service	1,877		3,374
Total property, plant and equipment	$	46,441	$	43,203
Less: accumulated depreciation and amortization	14,580		12,676
Property, plant and equipment, net	$	31,861	$	30,527

Debt (Tables)

3 Months Ended

Mar. 30, 2019

Debt Disclosure [Abstract]

Schedule of debt balances

The Company’s debt balances are detailed below:



(in thousands)	March 30, 2019			December 31, 2018
2018 Revolving Credit Facility (defined below)	$	6,000		$	6,000
2018 Term Loan Facility (defined below)	20,000			20,000
Equipment financing loan	5,000			5,000
Debt issuance costs	(553		)	(612		)
Total debt outstanding	$	30,447		$	30,388
Less: current portion of long-term debt	—			—
Long-term debt	$	30,447		$	30,388

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Share-Based Compensation (Tables)

3 Months Ended

Mar. 30, 2019

Share-based Payment Arrangement [Abstract]

Schedule of stock option activity

The following table summarizes the Company’s stock option activity during the three months ended March 30, 2019:



	Number of Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value (in thousands)⁽¹⁾
Outstanding at December 31, 2018	5,120,293		$	3.13	7.3	$	81,371
Granted	—		$	—	—	$	—
Exercised	(169,583	)	$	2.16	—	$	2,859
Cancelled/Forfeited	(50,382	)	$	4.34	—	$	—
Outstanding at March 30, 2019	4,900,328		$	3.15	7.0	$	80,076
Vested and exercisable at March 30, 2019	2,981,633		$	1.11	5.9	$	54,793
Vested and expected to vest at March 30, 2019	3,967,483		$	2.16	5.9	$	68,759

__________

Schedule of restricted stock activity

The following table summarizes the Company’s restricted stock activity during the three months ended March 30, 2019:



	Number of Shares of Restricted Stock		Weighted Average Remaining Contractual Life (Years)	Weighted Average Grant Date Fair Value Per Share
Outstanding at December 31, 2018	100,127		1.6	$	17.03
Granted	—		—	$	—
Vested/Released	(12,946	)	—	$	—
Cancelled/Forfeited	—		—	$	—
Outstanding at March 30, 2019	87,181		1.4	$	17.03

Net Loss Per Share Attributable to Common Stockholders (Tables)

3 Months Ended

Mar. 30, 2019

Earnings Per Share [Abstract]

Schedule of basic and diluted net loss per common share

Basic and diluted net loss per common share was the same for each period presented, as the inclusion of all potential common shares outstanding would have been antidilutive.



(in thousands, except share and per share amounts)	Three Months Ended
(in thousands, except share and per share amounts)	March 30, 2019			March 31, 2018
Numerator:
Net loss attributable to common stockholders	$	(6,649	)	$	(5,696	)
Denominator:
Weighted average common shares outstanding—basic	6,974,301			5,793,801
Dilutive effect of stock equivalents resulting from stock options, common stock warrants, preferred stock warrants and convertible preferred stock (as converted)	—			—
Weighted average common shares outstanding—diluted	6,974,301			5,793,801
Net loss per common share—basic and diluted	$	(0.95	)	$	(0.98	)

Schedule of antidilutive securities excluded from computation of earnings per share



	March 30, 2019	March 31, 2018
Convertible preferred stock (as converted)	41,562,111	39,474,156
Preferred stock warrants (as converted to common stock warrants and subsequently exercised)	160,767	160,767
Common stock warrants (as exercised)	60,002	—
Total	41,782,880	39,634,923

Introduction (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	May 06, 2019	Mar. 30, 2019	Mar. 31, 2018
Subsidiary, Sale of Stock [Line Items]
Sale of stock, issuance costs		$ 946	$ 0
Subsequent event
Subsidiary, Sale of Stock [Line Items]
Underwriting discounts and commissions	$ 19,400
Subsequent event \| IPO
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	11,068,750
Sale of stock, price per share (in dollars per share)	$ 25.00
Proceeds from IPO, net	$ 252,500
Sale of stock, issuance costs	$ 4,800
Number of common stock shares converted	41,562,111
Number of shares issued for each share of convertible preferred stock converted (in shares)	1
Subsequent event \| Over-allotment option
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	1,443,750
Common Stock \| Subsequent event \| IPO
Subsidiary, Sale of Stock [Line Items]
Number of shares able to purchase	160,767

Summary of Significant Accounting Policies - Narrative (Details)						1 Months Ended			3 Months Ended
	Apr. 29, 2019 shares	Apr. 18, 2019 shares	Apr. 03, 2019 shares	Jan. 02, 2019	Mar. 02, 2016 USD ($)	Dec. 31, 2016 USD ($)	Feb. 28, 2016 USD ($) shares	Oct. 31, 2015 USD ($)	Mar. 30, 2019 USD ($) $ / shares shares	Mar. 31, 2018 USD ($)	May 06, 2019 shares	Dec. 31, 2018 USD ($)	Jun. 30, 2018 $ / shares shares
Class of Warrant or Right [Line Items]
Stock split, conversion ratio				1.5
Deferred offering costs									$ 3,400,000			$ 3,200,000
Liability for estimated sales discounts									900,000			$ 800,000
Cost of goods sold									$ 29,435,000	$ 10,719,000
Stock options granted (in shares) \| shares									0
Common Stock \| Line of credit \| SVB Credit Facilities
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) \| shares									60,002				60,002
Exercise price (in dollars per share) \| $ / shares									$ 3.00				$ 3.00
Series B
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) \| shares									121,694				121,694
Exercise price (in dollars per share) \| $ / shares									$ 1.07				$ 1.07
Series E
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) \| shares									39,073				39,073
Exercise price (in dollars per share) \| $ / shares									$ 3.68				$ 3.68
IPO \| Subsequent event \| Common Stock
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) \| shares											160,767
Shipping and handling
Class of Warrant or Right [Line Items]
Cost of goods sold									$ 1,300,000	$ 1,100,000
Distributor one \| Customer concentration risk \| Revenue benchmark
Class of Warrant or Right [Line Items]
Concentration risk									21.00%	34.00%
Distributor two \| Customer concentration risk \| Revenue benchmark
Class of Warrant or Right [Line Items]
Concentration risk									21.00%	14.00%
Distributor three \| Customer concentration risk \| Revenue benchmark
Class of Warrant or Right [Line Items]
Concentration risk										11.00%
International \| Geographic concentration risk \| Revenue benchmark
Class of Warrant or Right [Line Items]
Concentration risk									14.00%
Donald Thompson
Class of Warrant or Right [Line Items]
Consulting fees, related party									$ 0	$ 47,162
Consulting agreement \| Executive Chair
Class of Warrant or Right [Line Items]
Monthly transaction amount					$ 20,210.33
Advisor agreement \| Food System Strategies, LLC
Class of Warrant or Right [Line Items]
Daily transaction amount								$ 4,000
Amended advisor agreement \| Food System Strategies, LLC
Class of Warrant or Right [Line Items]
Monthly transaction amount						$ 10,000	$ 25,000
2018 Plan \| Subsequent event
Class of Warrant or Right [Line Items]
Stock options granted (in shares) \| shares	51,999	1,000,000	264,033
Restricted stock unit \| 2018 Plan \| Executive Chair
Class of Warrant or Right [Line Items]
Fair value per share (in dollars per share)					$ 105,000
Vesting period					12 months
Termination period upon prior written notice					120 days
Breach, termination period upon prior written notice, non-breaching party					30 days
Non-qualified stock option \| Amended advisor agreement \| Food System Strategies, LLC
Class of Warrant or Right [Line Items]
Vesting period							3 years
Stock options granted (in shares) \| shares							798,848
Minimum \| Advisor agreement \| Food System Strategies, LLC
Class of Warrant or Right [Line Items]
Days of service								2 days
Minimum \| Amended advisor agreement \| Food System Strategies, LLC
Class of Warrant or Right [Line Items]
Days of service						5 days
Maximum \| Amended advisor agreement \| Food System Strategies, LLC
Class of Warrant or Right [Line Items]
Days of service						6 days

Summary of Significant Accounting Policies - Schedule of financial instruments measured at fair value (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability	$ 2,677	$ 1,918
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	2,677	1,918
Recurring \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	0	0
Recurring \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	0	0
Recurring \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	2,677	1,918
Preferred stock warrant liability \| Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability	1,998	1,441
Preferred stock warrant liability \| Recurring \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability	0	0
Preferred stock warrant liability \| Recurring \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability	0	0
Preferred stock warrant liability \| Recurring \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability	1,998	1,441
Common stock warrant liability \| Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability	679	477
Common stock warrant liability \| Recurring \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability	0	0
Common stock warrant liability \| Recurring \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability	0	0
Common stock warrant liability \| Recurring \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrant liability	$ 679	$ 477

Summary of Significant Accounting Policies - Schedule of assumptions used for valuation (Details)	Mar. 30, 2019 $ / shares	Mar. 31, 2018 $ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (in years)	2 years	3 years
Fair value of underlying shares (in dollars per share)	$ 19.49	$ 3.00
Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input (as a percent)	0.55	0.55
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input (as a percent)	0.0227	0.0198
Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input (as a percent)	0	0

Summary of Significant Accounting Policies - Summary of changes in fair value (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 1,918	$ 550
Change in fair value of warrant liability	759	129
Ending balance	$ 2,677	$ 679

Summary of Significant Accounting Policies - Schedule of net revenues by platform and channel (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Less: Discounts	$ (3,112)	$ (1,568)
Net revenues	40,206	12,776
Retail
Disaggregation of Revenue [Line Items]
Net revenues	19,579	9,288
Restaurant and Foodservice
Disaggregation of Revenue [Line Items]
Net revenues	20,627	3,488
Fresh Platform
Disaggregation of Revenue [Line Items]
Gross revenues	38,806	9,596
Frozen Platform
Disaggregation of Revenue [Line Items]
Gross revenues	$ 4,512	$ 4,748

Restructuring (Details) - USD ($)	3 Months Ended
Restructuring (Details) - USD ($)	Mar. 30, 2019	Mar. 31, 2018	Dec. 31, 2018
Restructuring and Related Activities [Abstract]
Restructuring expenses	$ 394,000	$ 294,000
Accrued unpaid liabilities, contract termination	$ 0		$ 0

Inventories - Schedule of major classes of inventory (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials and packaging	$ 16,385	$ 13,756
Work in process	6,198	2,517
Finished goods	11,698	13,984
Total	$ 34,281	$ 30,257

Property, Plant and Equipment - Summary of property, plant, and equipment (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 46,441	$ 43,203
Less: accumulated depreciation and amortization	14,580	12,676
Property, plant and equipment, net	31,861	30,527
Manufacturing equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	28,866	25,314
Research and development equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	7,111	6,088
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	7,166	7,080
Capital leases
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	883	882
Software
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	125	60
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	203	195
Vehicles
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	210	210
Assets not yet placed in service
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 1,877	$ 3,374

Property, Plant and Equipment - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 1,905	$ 733
Assets held-for-sale	1,900		$ 1,000
Cost of goods sold
Property, Plant and Equipment [Line Items]
Depreciation and amortization	1,400	600
Research and development expense
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 500	$ 100

Debt - Schedule of debt balances (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Debt issuance costs	$ (553)	$ (612)
Total debt outstanding	30,447	30,388
Less: current portion of long-term debt	0	0
Long-term debt	30,447	30,388
Loan facility \| 2018 Term Loan Facility
Debt Instrument [Line Items]
Debt, outstanding balance	20,000	20,000
Loan facility \| Equipment financing loan
Debt Instrument [Line Items]
Debt, outstanding balance	5,000	5,000
2018 Revolving Credit Facility \| Line of credit
Debt Instrument [Line Items]
Debt, outstanding balance	$ 6,000	$ 6,000

Debt - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended
Debt - Narrative (Details) - USD ($)	Jun. 30, 2018	Mar. 30, 2019	Mar. 31, 2018	May 06, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Debt issuance costs		$ 553,000			$ 612,000
Amortization of debt issuance costs		58,000	$ 9,000
Loan facility \| 2018 Term Loan Facility
Debt Instrument [Line Items]
Debt, outstanding balance		20,000,000			20,000,000
Loan facility \| Equipment financing loan
Debt Instrument [Line Items]
Debt, outstanding balance		5,000,000			$ 5,000,000
Interest expense		$ 100,000	0
Interest rate		11.75%			11.50%
Line of credit \| SVB Credit Facilities
Debt Instrument [Line Items]
Interest expense		$ 600,000	$ 18,000
Line of credit \| 2018 Term Loan Facility
Debt Instrument [Line Items]
Current borrowing capacity		$ 0
Interest rate		9.50%
Line of credit \| 2018 Revolving Credit Facility
Debt Instrument [Line Items]
Debt, outstanding balance		$ 6,000,000			$ 6,000,000
Variable annual interest rate, additional upon default	5.00%
Current borrowing capacity		$ 0
Interest rate		6.25%
Advance at closing \| Loan facility \| 2018 Term Loan Facility
Debt Instrument [Line Items]
Debt, face amount	$ 10,000,000.0
Variable annual interest rate	4.00%
Advance at closing \| Loan facility \| 2018 Revolving Credit Facility
Debt Instrument [Line Items]
Debt, face amount	$ 6,000,000.0
Advance if no event of default through borrowing date \| Loan facility \| 2018 Term Loan Facility
Debt Instrument [Line Items]
Debt, face amount	5,000,000.0
Advance if no event of default, based on minimum level of gross profit \| Loan facility \| 2018 Term Loan Facility
Debt Instrument [Line Items]
Debt, face amount	$ 5,000,000.0
Minimum \| Line of credit \| 2018 Revolving Credit Facility
Debt Instrument [Line Items]
Variable annual interest rate	0.75%
Maximum \| Line of credit \| 2018 Revolving Credit Facility
Debt Instrument [Line Items]
Variable annual interest rate	1.25%
Common Stock \| Line of credit \| SVB Credit Facilities
Debt Instrument [Line Items]
Number of warrants issued (in shares)	60,002	60,002
Exercise price (in dollars per share)	$ 3.00	$ 3.00
Series B
Debt Instrument [Line Items]
Number of warrants issued (in shares)	121,694	121,694
Exercise price (in dollars per share)	$ 1.07	$ 1.07
Series E
Debt Instrument [Line Items]
Number of warrants issued (in shares)	39,073	39,073
Exercise price (in dollars per share)	$ 3.68	$ 3.68
IPO \| Subsequent event \| Common Stock
Debt Instrument [Line Items]
Number of warrants issued (in shares)				160,767

Stockholders’ Deficit and Convertible Preferred Stock (Details) - $ / shares	May 06, 2019	Mar. 30, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Class of Stock [Line Items]
Common stock, authorized (in shares)		60,000,000	58,669,600
Common stock, par value (in dollars per share)		$ 0.0001	$ 0.0001
Common stock, issued (in shares)		7,120,933	6,951,350
Common stock, outstanding (in shares)		7,120,933	6,951,350
Convertible preferred stock, authorized (in shares)		43,882,867	43,882,867
Convertible preferred stock, par value (in shares)		$ 0.0001	$ 0.0001
Convertible preferred stock, outstanding (in shares)		41,562,111	41,562,111	39,474,156	39,361,211
Series A
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		3,333,500	3,333,500
Convertible preferred stock, par value (in shares)		$ 0.0001	$ 0.0001
Convertible preferred stock, issued (in shares)		3,333,500	3,333,500
Convertible preferred stock, outstanding (in shares)		3,333,500	3,333,500
Series B
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		4,802,260	4,802,260
Convertible preferred stock, par value (in shares)		$ 0.0001	$ 0.0001
Convertible preferred stock, issued (in shares)		4,680,565	4,680,565
Convertible preferred stock, outstanding (in shares)		4,680,565	4,680,565
Series C
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		8,076,643	8,076,643
Convertible preferred stock, par value (in shares)		$ 0.0001	$ 0.0001
Convertible preferred stock, issued (in shares)		8,076,636	8,076,636
Convertible preferred stock, outstanding (in shares)		8,076,636	8,076,636
Series D
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		8,713,207	8,713,207
Convertible preferred stock, par value (in shares)		$ 0.0001	$ 0.0001
Convertible preferred stock, issued (in shares)		8,713,201	8,713,201
Convertible preferred stock, outstanding (in shares)		8,713,201	8,713,201
Series E
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		4,740,531	4,740,531
Convertible preferred stock, par value (in shares)		$ 0.0001	$ 0.0001
Convertible preferred stock, issued (in shares)		4,701,449	4,701,449
Convertible preferred stock, outstanding (in shares)		4,701,449	4,701,449
Series F
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		4,866,776	4,866,776
Convertible preferred stock, par value (in shares)		$ 0.0001	$ 0.0001
Convertible preferred stock, issued (in shares)		4,866,758	4,866,758
Convertible preferred stock, outstanding (in shares)		4,866,758	4,866,758
Series G
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		5,140,257	5,140,257
Convertible preferred stock, par value (in shares)		$ 0.0001	$ 0.0001
Convertible preferred stock, issued (in shares)		5,114,786	5,114,786
Convertible preferred stock, outstanding (in shares)		5,114,786	5,114,786
Series H
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)		4,209,693	4,209,693
Convertible preferred stock, par value (in shares)		$ 0.0001	$ 0.0001
Convertible preferred stock, issued (in shares)		2,075,216	2,075,216
Convertible preferred stock, outstanding (in shares)		2,075,216	2,075,216
Subsequent event
Class of Stock [Line Items]
Common stock, authorized (in shares)	500,000,000
Common stock, par value (in dollars per share)	$ 0.0001
IPO \| Subsequent event
Class of Stock [Line Items]
Convertible preferred stock, authorized (in shares)	500,000
Convertible preferred stock, par value (in shares)	$ 0.0001
Number of common stock shares converted	41,562,111
Number of shares issued for each share of convertible preferred stock converted (in shares)	1

Share-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions						1 Months Ended		3 Months Ended		12 Months Ended	93 Months Ended	96 Months Ended
	Apr. 30, 2019	Apr. 29, 2019	Apr. 18, 2019	Apr. 03, 2019	Nov. 15, 2018	Apr. 30, 2019	Oct. 31, 2018	Mar. 30, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2018	Mar. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding (in shares)								4,900,328		5,120,293	5,120,293	4,900,328
Shares issued (in shares)											4,335,331	4,504,914
Stock options granted (in shares)								0
Exercise price (in dollars per share)								$ 0.00
2011 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)								9,462,455				9,462,455
Shares available for grant (in shares)								57,213		6,859	6,859	57,213
2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)								4,577,114				4,577,114
Granted in period, effective upon registration (in shares)								50,000
Subsequent event \| 2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)	14,482,356					14,482,356
Stock options granted (in shares)		51,999	1,000,000	264,033
Exercise price (in dollars per share)				$ 20.02
Granted (in shares)			99,433
Purchase price (in dollars per share)			$ 0.01
Beginning 2020 fiscal year \| Subsequent event \| 2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized annually (in shares)	2,144,521
Percent of common stock outstanding, per year	4.00%
Employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense								$ 0.6	$ 0.2
Unrecognized compensation expense								$ 2.3		$ 2.4	$ 2.4	$ 2.3
Unrecognized compensation expense, period of recognition								2 years 8 months 12 days		2 years 10 months 24 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)							135,791	0
Purchase price (in dollars per share)							$ 0.02
Share-based compensation expense								$ 0.3
Unrecognized compensation expense, period of recognition								1 year 4 months 24 days
Fair value per share (in dollars per share)							$ 17.03	$ 17.03		$ 17.03	$ 17.03	$ 17.03
Unrecognized share-based compensation expense								$ 1.4				$ 1.4
Restricted Stock \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							12 months
Restricted Stock \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							24 months
Restricted Stock \| Subsequent event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)						99,433
Purchase price (in dollars per share)	$ 0.02					$ 0.02
Fair value per share (in dollars per share)	$ 20.02					$ 20.02
Vesting period	24 months
IPO \| 2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (in dollars per share)								$ 25.00
Employee Stock \| 2018 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)					804,195
Additional shares authorized annually (in shares)					536,130
Percent of common stock outstanding, per year					1.00%
Period of additional shares authorized					10 years

Share-Based Compensation - Schedule of stock option activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 30, 2019	Dec. 31, 2018
Number of Stock Options
Outstanding, beginning balance (in shares)	5,120,293
Granted (in shares)	0
Exercised (in shares)	(169,583)
Cancelled/Forfeited (in shares)	(50,382)
Outstanding, ending balance (in shares)	4,900,328	5,120,293
Weighted Average Exercise Price
Outstanding, beginning balance (in dollars per share)	$ 3.13
Granted (in dollars per share)	0.00
Exercised (in dollars per share)	2.16
Cancelled/Forfeited (in shares)	4.34
Outstanding, ending balance (in dollars per share)	$ 3.15	$ 3.13
Aggregate Intrinsic Value
Outstanding at December 31, 2018	$ 81,371
Granted	$ 0
Exercised	$ 2,859
Cancelled/Forfeited	$ 0
Outstanding at March 30, 2019	$ 80,076	$ 81,371
Stock Option Activity, Additional Disclosures
Weighted average remaining contractual life, outstanding	7 years	7 years 4 months
Weighted average remaining contractual life, vested and exercisable	5 years 10 months 24 days
Weighted average remaining contractual life, vested and expected to vest	5 years 10 months 24 days
Vested and exercisable (in shares)	2,981,633
Vested and expected to vest (in shares)	3,967,483
Vested and exercisable (in dollars per share)	$ 1.11
Vested and expected to vest (in dollars per share)	$ 2.16
Aggregate intrinsic value, vested and exercisable	$ 54,793
Aggregate intrinsic value, vested and expected to vest	$ 68,759

Share-Based Compensation - Schedule of restricted stock activity (Details) - Restricted Stock - $ / shares	1 Months Ended	3 Months Ended	12 Months Ended
	Oct. 31, 2018	Mar. 30, 2019	Dec. 31, 2018
Number of Shares of Restricted Stock
Outstanding, beginning balance (in shares)		100,127
Granted (in shares)	135,791	0
Vested/Released (in shares)		(12,946)
Cancelled/Forfeited (in shares)		0
Outstanding, ending balance (in shares)		87,181	100,127
Restricted Stock Activity, Additional Disclosures
Weighted Average Remaining Contractual Life (Years)		1 year 4 months 24 days	1 year 7 months 6 days
Weighted Average Grant Date Fair Value Per Share (in dollars per share)	$ 17.03	$ 17.03	$ 17.03

Commitments and Contingencies (Details) $ in Millions	1 Months Ended
Commitments and Contingencies (Details) $ in Millions	Oct. 31, 2018 defendant	Mar. 30, 2019 USD ($)
Lease Obligations
Lease term		5 years
Aggregate lease amount		$ 2.7
Lease obligation due through 2023		2.6
Lease obligation due annually, 2019		0.5
Lease obligation due annually, 2020		0.5
Lease obligation due annually, 2021		0.5
Lease obligation due annually, 2022		0.5
Lease obligation due annually, 2023		0.5
Lease obligation due thereafter		0.1
Purchase commitments		$ 46.1
Former co-manufacturer complaint \| Pending litigation
Lease Obligations
Number of defendants \| defendant	1

Income Taxes (Details) - USD ($)	3 Months Ended
Income Taxes (Details) - USD ($)	Mar. 30, 2019	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0
Accrued interest or penalties related to uncertain tax positions	$ 0

Net Loss Per Share Attributable to Common Stockholders - Schedule of basic and diluted net loss per common share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Numerator:
Net loss attributable to common stockholders	$ (6,649)	$ (5,696)
Denominator:
Weighted average common shares outstanding—basic and diluted (in shares)	6,974,301	5,793,801
Dilutive effect of stock equivalents resulting from stock options, common stock warrants, preferred stock warrants and convertible preferred stock (as converted) (in shares)	0	0
Weighted average common shares outstanding-diluted (in shares)	6,974,301	5,793,801
Net loss per common share—basic and diluted (in dollars per share)	$ (0.95)	$ (0.98)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Net Loss Per Share Attributable to Common Stockholders - Schedule of antidilutive securities excluded from computation of earnings per share (Details) - shares	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities (in shares)	41,782,880	39,634,923
Convertible preferred stock (as converted)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities (in shares)	41,562,111	39,474,156
Preferred stock warrants (as converted to common stock warrants and subsequently exercised)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities (in shares)	160,767	160,767
Common stock warrants (as exercised)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities (in shares)	60,002	0

Statements of Convertible Preferred Stock and Stockholders’ Deficit (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2018 USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 7